James Fleming, MD
Family Medicine · Latta, SCNPI 1841525631
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 26.2% of the total. 2025 is the largest year on record at $683, 3.5 times the $198 reported in 2019.
Across 150 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$656
- GSK$334
- Novo Nordisk$249
- Lilly USA, LLC$244
- Vanda Pharmaceuticals Inc.$226
- Alkermes, Inc.$135
- plus $659 from 20 others
What the payments were for
- Food & beverage$2,502100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $656 |
| GSK | 21 | $334 |
| Novo Nordisk | 17 | $249 |
| Lilly USA, LLC | 15 | $244 |
| Vanda Pharmaceuticals Inc. | 8 | $226 |
| Alkermes, Inc. | 6 | $135 |
| Bayer | 7 | $116 |
| Novartis | 6 | $87 |
| Corcept Therapeutics | 3 | $70 |
| AstraZeneca | 4 | $68 |
| Xeris Pharmaceuticals, Inc. | 3 | $47 |
| Exact Sciences | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Astellas Pharma US Inc | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Abbott | 1 | $18 |
| Insulet Corporation | 1 | $18 |
| Merck | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Braeburn Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Pfizer | 1 | $14 |
| Amgen | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $3 |
How this compares
$2,502 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $104,016 |
| JardianceEmpagliflozin | 61 | $79,360 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 52 | $64,063 |
| MounjaroTirzepatide | 23 | $52,454 |
| OzempicSemaglutide | 24 | $41,360 |
| JanuviaSitagliptin Phosphate | 30 | $40,154 |
| EliquisApixaban | 18 | $20,162 |
| EntrestoSacubitril/Valsartan | 13 | $18,181 |
| TradjentaLinagliptin | 14 | $16,968 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $11,578 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $9,214 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 20 | $8,771 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 135 | $6,851 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $6,536 |
| Celecoxib | 157 | $5,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $334 | $113,23084 claims |
| MerckJanumet Xr, Januvia | $17 | $104,21782 claims |
| Boehringer IngelheimJardiance, Tradjenta | $21 | $96,32775 claims |
| Lilly USA, LLCMounjaro | $244 | $52,45423 claims |
| Novo NordiskOzempic | $249 | $41,36024 claims |
| PfizerEliquis | $14 | $20,16218 claims |
| NovartisEntresto | $87 | $18,18113 claims |
| AstraZenecaSymbicort | $68 | $5,23914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Latta
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Jeffrey BroderNorth Augusta$140K
- Terry NagelColumbia$112K
- Katherine JohnsonGreenwood$80K
- Scott SmithMount Pleasant$68K
- Jennifer StolinSummerville$59K
- Nicholas PenningsNorth Myrtle Beach$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.